Organization | Genethon

Genethon Report issue

For profit Phase 2

Founded: Evry France (1990)

Organization Overview

First Clinical Trial

2011

NCT01347242

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2021

Timeline

NOW

Now

Alternative names

Genethon

Active Ingredients

Drugs in Phase 2 Trials (6)

autologous cd34+ cells transduced with wasp lentiviral vector (1 trial)

autologous cd34 positive cells transduced with a lentiviral vector containing human was gene (2 trials)

gnt0003 (1 trial)

lentiviral g1xcgd (1 trial)

valproic acid (depakene) (1 trial)

x vivo gene therapy (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Cardiomyopathies (Phase 2)

Crigler-Najjar Syndrome (Phase 2)

Granuloma (Phase 2)

Granulomatous Disease, Chronic (Phase 2)

Syndrome (Phase 2)

Wiskott-Aldrich Syndrome (Phase 2)

Overview

Highest Phase: Phase 2
# of Trials: 8
# of Trial APIs: 6